Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.81 Insider Own4.05% Shs Outstand12.91M Perf Week1.55%
Market Cap67.52M Forward P/E- EPS next Y-3.95 Insider Trans0.00% Shs Float12.80M Perf Month-42.40%
Income-63.90M PEG- EPS next Q-1.28 Inst Own57.40% Short Float7.42% Perf Quarter-41.17%
Sales- P/S- EPS this Y66.30% Inst Trans1.33% Short Ratio4.48 Perf Half Y-49.61%
Book/sh5.94 P/B0.88 EPS next Y15.80% ROA309.20% Target Price7.00 Perf Year-60.08%
Cash/sh5.91 P/C0.88 EPS next 5Y5.60% ROE491.70% 52W Range4.71 - 15.40 Perf YTD-48.98%
Dividend- P/FCF- EPS past 5Y20.20% ROI- 52W High-66.07% Beta2.29
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low10.93% ATR0.44
Employees72 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)29.97 Volatility4.52% 6.38%
OptionableYes Debt/Eq0.00 EPS Q/Q39.40% Profit Margin- Rel Volume0.67 Prev Close5.23
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout0.00% Avg Volume211.95K Price5.22
Recom3.30 SMA20-13.18% SMA50-32.17% SMA200-47.75% Volume137,318 Change-0.10%
Oct-07-16Downgrade JP Morgan Overweight → Neutral
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Jul-10-18 04:55PM  Ex-biopharmaceutical employees convicted in U.S. of insider trading Reuters
Jul-02-18 04:15PM  Merrimack Secures $25 Million Debt Facility with Hercules Capital PR Newswire
Jun-27-18 08:12AM  Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod Zacks +7.26%
Jun-26-18 07:51PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
08:12AM  Merrimack Crashes as Phase II Pancreatic Cancer Study Fails Zacks
Jun-25-18 07:55AM  Merrimack to scrap development of pancreatic cancer treatment Reuters -43.83%
07:54AM  UPDATE: Merrimack Pharma shares slide 34% after trial of pancreatic cancer treatment fails to meet main goals MarketWatch
07:29AM  Merrimack to scrap development of pancreatic cancer treatment Reuters
07:20AM  Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer PR Newswire
Jun-15-18 08:41AM  Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock Zacks
Jun-07-18 09:15AM  Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report? Zacks
Jun-04-18 01:57PM  Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-29-18 08:15AM  Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience, Merrimack Pharmaceuticals, and Energizer with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting PR Newswire
May-09-18 10:49AM  Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 Zacks
May-08-18 06:25AM  Merrimack Reports First Quarter 2018 Financial Results PR Newswire
May-03-18 10:13AM  What's in the Cards for Merrimack (MACK) in Q1 Earnings? Zacks
May-01-18 07:00AM  Merrimack Announces Timing of First Quarter 2018 Investor Conference Call PR Newswire
Apr-09-18 07:30AM  Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
Apr-04-18 08:15AM  Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail Fundamental Analysis, Key Performance Indications GlobeNewswire +5.74%
Mar-14-18 07:30AM  Wired News Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer ACCESSWIRE
Mar-13-18 09:45AM  Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 Zacks
Mar-12-18 07:06PM  Edited Transcript of MACK earnings conference call or presentation 12-Mar-18 12:30pm GMT Thomson Reuters StreetEvents -10.28%
07:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:27AM  Merrimack Provides Business Update and Reports 2017 Financial Results PR Newswire
06:25AM  Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer PR Newswire
Mar-05-18 07:00AM  Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference PR Newswire
Feb-27-18 05:11AM  Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Incs (NASDAQ:MACK)? Simply Wall St.
Feb-26-18 06:55AM  Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer PR Newswire
Feb-23-18 09:10AM  What's in the Cards for Merrimack (MACK) in Q4 Earnings? Zacks
Feb-20-18 07:00AM  Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology PR Newswire
Feb-15-18 07:00AM  Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference PR Newswire
Feb-06-18 08:25AM  New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-04-18 08:00AM  Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-11-17 04:12AM  Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound? Zacks
Nov-30-17 06:50AM  Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors PR Newswire
Nov-20-17 08:04PM  With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Incs (MACK) Management Done A Good Job? Simply Wall St.
Nov-14-17 07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 08:31PM  Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 09:45AM  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Zacks
Nov-08-17 10:15AM  Merrimack beats 3Q profit forecasts Associated Press
08:25AM  Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss Zacks
06:40AM  Merrimack Reports Third Quarter 2017 Financial Results PR Newswire
06:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-17 10:17AM  What's in the Cards for Merrimack (MACK) in Q3 Earnings? Zacks
Nov-01-17 07:10AM  Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer ACCESSWIRE
06:55AM  Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call PR Newswire
Oct-30-17 09:45AM  Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121 SmarterAnalyst
09:32AM  NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers TheStreet.com
06:55AM  Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer PR Newswire
Oct-28-17 10:41AM  Have Investors Already Priced In Merrimack Pharmaceuticals Incs (MACK) Growth? Simply Wall St.
Oct-13-17 07:30AM  Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020 PR Newswire
Oct-10-17 09:21PM  Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio? Simply Wall St.
04:23PM  Merrimack Announces Settlement of Convertible Note Litigation PR Newswire
Sep-20-17 04:15PM  Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)? Simply Wall St.
Sep-07-17 08:00AM  Today's Research Reports on Trending Tickers: American Superconductor and Merrimack Pharmaceuticals ACCESSWIRE +8.74%
Aug-31-17 09:39AM  Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers TheStreet.com
08:00AM  Merrimack Announces Date of One-for-Ten Reverse Stock Split PR Newswire
Aug-14-17 06:55AM  Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer PR Newswire
Aug-13-17 01:35AM  Edited Transcript of MACK earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 10:16AM  Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls Zacks
Aug-09-17 10:59PM  Merrimack misses 2Q profit forecasts Associated Press
07:23AM  Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss Zacks
06:55AM  Merrimack Reports Second Quarter 2017 Financial Results PR Newswire
06:10AM  Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-17 07:00AM  Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call PR Newswire
Aug-01-17 04:52PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : August 1, 2017 Capital Cube
Jul-28-17 11:18AM  What's in the Cards for Merrimack (MACK) in Q2 Earnings? Zacks
Jul-24-17 06:55AM  Merrimack Appoints Thomas Needham as Chief Business Officer PR Newswire
Jun-27-17 09:51AM  Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
Jun-22-17 08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Moleculin Biotech and Merrimack Pharmaceuticals Accesswire +11.45%
Jun-21-17 03:43PM  These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Motley Fool
Jun-20-17 10:33AM  Merrimack Completes Enrollment in Phase II Study for MM-141 Zacks +6.72%
Jun-19-17 06:55AM  Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 PR Newswire
Jun-14-17 04:24AM  Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report? Zacks -5.93%
Jun-08-17 06:55AM  Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources PR Newswire +8.63%
May-31-17 04:55PM  Why iRobot, Golar LNG, and Merrimack Pharmaceuticals Slumped Today Motley Fool -23.26%
10:58AM  Why Merrimack Pharmaceuticals Stock Is Tanking Today Motley Fool
May-25-17 04:30PM  Merrimack Announces Management Change PR Newswire
May-16-17 05:11AM  Edited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents -6.38%
May-11-17 10:25AM  Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde Zacks
08:30AM  Edited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 08:19AM  Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss Zacks +5.92%
08:00AM  Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call Accesswire
06:52AM  Merrimack reports 1Q loss Associated Press
06:45AM  Merrimack Reports First Quarter 2017 Financial Results PR Newswire
May-02-17 04:30PM  Merrimack Announces Timing of First Quarter 2017 Investor Conference Call PR Newswire
Apr-27-17 12:03PM  What's in the Cards for Merrimack (MACK) in Q1 Earnings? Zacks
Apr-19-17 03:07PM  Merrimack Pharmaceuticals, Inc. Value Analysis (NASDAQ:MACK) : April 19, 2017 Capital Cube
Apr-18-17 08:32AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 18, 2017 Capital Cube
Apr-17-17 07:00AM  Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research PR Newswire
Apr-05-17 04:05PM  Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale PR Newswire
Apr-04-17 08:05AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 4, 2017 Capital Cube
Apr-03-17 11:30AM  Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310 PR Newswire
Mar-31-17 08:58AM  Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock? Zacks
Mar-30-17 12:11PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
12:00PM  Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion PR Newswire
Mar-27-17 07:00AM  Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting PR Newswire
Mar-24-17 02:45PM  Merrimack (MACK) Starts Enrollment in Solid Tumors Study Zacks
Mar-23-17 01:20PM  Merrimack asset sale prompts legal blowback at bizjournals.com
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nielsen Ulrik B.DirectorSep 15Option Exercise13.207,796102,90730,477Sep 15 04:43 PM
Nielsen Ulrik B.DirectorSep 15Sale14.237,796110,93722,681Sep 15 04:43 PM
Nielsen Ulrik B.DirectorSep 14Option Exercise13.201001,32022,781Sep 15 04:43 PM
Nielsen Ulrik B.DirectorSep 14Sale14.201001,42022,681Sep 15 04:43 PM
Nielsen Ulrik B.DirectorSep 13Option Exercise13.206,80089,76029,481Sep 13 05:38 PM
Nielsen Ulrik B.DirectorSep 13Sale14.276,80097,03622,681Sep 13 05:38 PM
Nielsen Ulrik B.DirectorSep 11Option Exercise13.2014,756194,77937,437Sep 13 05:38 PM
Nielsen Ulrik B.DirectorSep 11Sale14.4614,756213,37222,681Sep 13 05:38 PM